



YHP COVID Medicines Service – Single Point of Access (HNY Region)

It has been brought to our attention that the oral COVID-19 treatments molnupiravir (Lagevrio®) and nirmatrelvir/ritonavir (Paxlovid®) have recently been added to the Directory of Medicines and Devices (DM&D) which means the medication could be printed onto an FP10 or sent via EPS.

In the Humber and North Yorkshire (HNY) area, Yorkshire Health Partners (YHP) are the commissioned Single Point of Access service who triage the patient and if appropriate arrange for medication to be supplied by currently only a small number of community pharmacies across the area who have been allocated stock via a locally commissioned service. These pharmacies can only supply following a referral from YHP and not against an EPS prescription or FP10.

If a patient or their representative presents to a pharmacy requesting information about how to access COVID-19 antiviral treatment, please advise them to contact their GP or ring 111 to receive the appropriate onward referral to specialist triage and consultation.

If a patient or their representative presents to a pharmacy with an EPS or FP10 prescription for molnupiravir (Lagevrio®) and nirmatrelvir/ritonavir (Paxlovid®) please advise the patient or their representative that all community pharmacies are unable to supply these medicines and they need to be referred into a specialist triage and consultation by either 111 or their GP.

The only stock currently available is supplied by the DHSC and there is no current route for community pharmacies to obtain this stock via usual mainline wholesale distribution channels. Issuing a prescription to a patient would result in a delay in treatment as patients would not be able to find a pharmacy that is able to source DHSC stock.